Hydralazine Valproate for Ovarian Cancer

Condition(s) targeted: Ovarian Cancer

Intervention: Hydralazine and magnesium valproate (Drug); Placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: National Institute of Cancerología

Official(s) and/or principal investigator(s):
Dolores Gallardo, MD, Principal Investigator, Affiliation: Instituto Nacional de Cancerologia

Overall contact:
Alfonso Dueñas-Gonzalez, MD PhD, Phone: +5255 56280486

The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or gemcitabine, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.

Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus topotecan over placebo plus topotecan upon progression-free survival.

Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase progression-free survival from 6 to 9 months as compared with the same regimen of chemotherapy plus placebo.

Official title: Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: Progression-Free Survival

Secondary outcome: Safety, response, overall survival.

Detailed description: Randomized, double-blind phase III trial. A total of 211 patients (alpha 0. 5, power 0. 8)with cisplatin-resistant recurrent or persistent cancer will be randomized to topotecan + placebo or topotecan + hydralazine + valproate for 6 courses every 4 weeks. Patients will receive an oral dose of hydralazine of 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t. i.d. Both drugs in a slow-release formulation. Experimental drugs or placebo will start from seven days before day 1 of chemotherapy until the end of the sixth course.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Measurable or evaluable disease(evaluable according to CA125 criteria of GCIG)

Cisplatin resistant ovarian cancer

- Persistent or progression to first line platinum-based chemotherapy

- Relapse within 6 months after completing first line platinum-based chemotherapy

- Platinum-sensitive disease who are failed to second line therapy based on platinum.

- Adequate organic function as defined by: hemoglobin >10 g/L, leukocytes >4000/mm3,

platelets >100 000mm3; normal creatinine value and creatinine clearance >60 mL/min; total bilirubin < 1. 5 upper normal limit value

Exclusion Criteria:

- History of allergy to hydralazine or valproate;

- Past or present condition of rheumatic disease, central nervous system disease, heart

failure from aortic stenosis and postural hypotension as diagnosed by a physician;

- Newly diagnosed hypertension patients with or without pharmacological treatment are

allowed as long as their treatment do not include hydralazine.

- Previous use of the experimental drugs (hydralazine and magnesium valproate) as well

as if patients were pregnant or breast-feeding.

Other exclusion criteria are uncontrolled systemic disease or infection.

Alfonso Dueñas-Gonzalez, MD PhD, Phone: +5255 56280486

Instituto Nacional de Cancerologia, Mexico City, Tlalpan 14080, Mexico; Recruiting
Dolores Gallardo, MD, Principal Investigator

Starting date: August 2007
Ending date: December 2009
Last updated: September 20, 2007